This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


GlaxoSmithKline plc

Drug Names(s): AEG40826

Description: HGS1029 is a potent small-molecule inhibitor of multiple IAP (inhibitor of apoptosis) protein family members. When IAP proteins are over-expressed in cancer cells, they may help cancer cells resist apoptosis, or programmed cell death, and resume growth.

Deal Structure: Human Genome Sciences and Aegera
In December 2007, Human Genome Sciences and Aegera Therapeutics announced an agreement under which HGS has acquired exclusive worldwide rights (excluding Japan) to develop and commercialize AEG40826 and related backup compounds to be chosen during a three-year research collaboration.

Under the agreement, HGS has paid Aegera an upfront license fee of $15 million and has made an equity investment of C$5 million. Aegera will be entitled to receive up to $295 million in future development and commercial milestone payments, including a $5 million milestone payment upon FDA clearance of an IND. Aegera will receive double-digit royalties on net sales in the HGS territory. In North America, Aegera will have the option to co-promote, under which it will share certain expenses and profits (30%) in lieu of its royalties.

GlaxoSmithKline and Human Genome Sciences
In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a...See full deal structure in Biomedtracker

Partners: Aegera Therapeutics, Inc.

HGS1029 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug